太阳大气是由磁场主导的巨大等离子体环境，提高太阳磁场观测精度，对太阳物理基础研究、空间天气 预报等都有十分重要的意义。中国科学院国家天文台研究员、AIMS项目负责人邓元勇介绍，"可以说， 磁场是太阳物理的第一观测量。" 过去，对太阳磁场的观测以分辨率为第一追求，对测量精度重视不够，国际上的大口径太阳望远镜测量 精度普遍在100高斯量级。随着科学研究不断深入，学界逐渐认识到，太阳上的弱磁场研究同样重要， 只重视分辨率远远不够，不光要"看得更清"，还要"量得更准"。 "就像拍照片和拍X光片时看到的人体不同，在不同波段观测到的太阳磁场反映的物理过程也不一 样。"中国科学院国家天文台研究员、AIMS项目技术负责人王东光说，"AIMS望远镜就是要补上太阳磁 场观测在中红外波段缺失的一环。" "我们以精确的磁场测量为突破口，抢占中红外波段太阳磁场观测先机，确保我国在太阳物理前沿观测 阵地上的领先地位。"锚定目标抓紧干，邓元勇带领团队进行攻关。 太阳，这颗距离地球最近的恒星，有诸多未解之谜待揭开。近日，全球首台中红外波段太阳磁场专用观 测设备（AIMS望远镜）正式启用，人类观测太阳又多了一双"慧眼"。 "十五五"规划建议提 ...

Core Viewpoint - The article discusses the rise of Chinese pharmaceutical companies in innovation and the challenges they face in collaborating with research institutions, highlighting a trust crisis in early-stage academic innovations [4][5][6]. Group 1: Innovation in Chinese Pharmaceutical Industry - In 2023, the total amount of new drug licensing transactions from Chinese pharmaceutical companies has exceeded $100 billion, indicating a significant rise in innovation capabilities [4]. - The market's increasing demand for innovation is leading to a more competitive international landscape for Chinese pharmaceutical companies [4]. Group 2: Challenges in Collaboration - Domestic research universities and institutions often face difficulties in industrial collaboration, with most partnerships occurring only after projects have reached advanced stages [5][6]. - There is a notable contrast with the U.S., where academic innovations are more readily supported by venture capital, reflecting a conservative approach in China towards early-stage academic innovations [5][6]. Group 3: Trust Issues and Funding - Trust issues arise when early-stage academic research fails to meet expectations, leading to terminated collaborations and a lack of investment in promising projects [7][12]. - The funding required for preclinical research ranges from 30 million to 50 million yuan, which poses a significant barrier for many projects [12]. Group 4: Need for Differentiated Investment - It is suggested that venture capital and large pharmaceutical companies allocate 5% to 10% of their R&D budgets to support early-stage, differentiated innovations, which could lead to breakthrough results [13]. - The article emphasizes the importance of nurturing both immediate and long-term innovations in the pharmaceutical industry, akin to planting seeds for future growth [13].

"十五五"规划建议提出，"加强基础研究战略性、前瞻性、体系化布局，提高基础研究投入比重， 加大长期稳定支持。"支撑高水平科技自立自强的源头创新，离不开基础研究的突破。AIMS望远镜的建 成启用，填补了国际上中红外波段太阳磁场观测的空白，也为后续大型天文设备在高海拔地区的建设提 供了重要参考。 图①：图为AIMS望远镜所在的塔楼。图②：现场的工程师们看到第一幅光谱图时，难掩内心的喜悦。 图③：团队正在检测引导光学系统成像质量。图④：团队正在检测主镜安装复位精度。以上图片均为中 国科学院国家天文台提供 太阳，这颗距离地球最近的恒星，有诸多未解之谜待揭开。近日，全球首台中红外波段太阳磁场专 用观测设备（AIMS望远镜）正式启用，人类观测太阳又多了一双"慧眼"。 "从0到1"的探索，打开太阳观测新窗口 太阳大气是由磁场主导的巨大等离子体环境，提高太阳磁场观测精度，对太阳物理基础研究、空间 天气预报等都有十分重要的意义。中国科学院国家天文台研究员、AIMS项目负责人邓元勇介绍，"可以 说，磁场是太阳物理的第一观测量。" 过去，对太阳磁场的观测以分辨率为第一追求，对测量精度重视不够，国际上的大口径太阳望远镜 测量精度普遍 ...

太阳大气是由磁场主导的巨大等离子体环境，提高太阳磁场观测精度，对太阳物理基础研究、空间天气 预报等都有十分重要的意义。中国科学院国家天文台研究员、AIMS项目负责人邓元勇介绍，"可以说， 磁场是太阳物理的第一观测量。" 过去，对太阳磁场的观测以分辨率为第一追求，对测量精度重视不够，国际上的大口径太阳望远镜测量 精度普遍在100高斯量级。随着科学研究不断深入，学界逐渐认识到，太阳上的弱磁场研究同样重要， 只重视分辨率远远不够，不光要"看得更清"，还要"量得更准"。 "就像拍照片和拍X光片时看到的人体不同，在不同波段观测到的太阳磁场反映的物理过程也不一 样。"中国科学院国家天文台研究员、AIMS项目技术负责人王东光说，"AIMS望远镜就是要补上太阳磁 场观测在中红外波段缺失的一环。" "我们以精确的磁场测量为突破口，抢占中红外波段太阳磁场观测先机，确保我国在太阳物理前沿观测 阵地上的领先地位。"锚定目标抓紧干，邓元勇带领团队进行攻关。 本报记者 李君强 图①：图为AIMS望远镜所在的塔楼。 图②：现场的工程师们看到第一幅光谱图时，难掩内心的喜悦。 图③：团队正在检测引导光学系统成像质量。 图④：团队正在检测主镜安 ...

此外，圆桌对话也探讨了技术创新与医学教育相融合的话题，例如让科研人员接触临床实践以培养转化 思维，走到临床中心的第一线去理解临床管理；以及开展高质量的多中心临床试验对于收集循证医学证 据、助力创新产品走向全球的重要性。在对话中，与会专家也呼吁，要重视跨学科、跨专业的协作，以 完成安全、高质量的研究；要用"登月"一般的雄心与愿景，共同推动创新。这场思想盛宴所碰撞出来的 智慧火花，为中国的医疗创新人才指明了前进方向。 围绕破解"全球技术落地难、本土创新转化慢"的问题，张珺表示，波士顿科学对中国的定位，早已超越 单纯的供应商或销售市场，而是将中国视为解决未来全球医疗健康问题大网络中的一块重要创新高地。 我们希望通过整合本土优质资源，更好地服务中国医患，这也清晰地体现在波士顿科学在华发展的三个 阶段：从本土智造，到深耕研发，再到共创医疗生态。展望未来，波士顿科学希望不仅是一个品牌，更 是深度融入中国医疗体系、充满活力的共建者。 谈及进入国内心血管医疗器械创新市场所遇到的难点，张珺也分享了当前医疗器械创新面临两大核心挑 战。一是创新转化之难。医疗器械创新涵盖材料、工程与临床等众多学科，是一项复杂的体系工程，打 通跨学科 ...

Core Insights - The Chinese pharmaceutical innovation sector has seen a significant increase in transaction amounts, surpassing $100 billion in overseas deals, indicating a robust growth in the industry [1][2] - The National Medical Products Administration (NMPA) approved 43 new drugs in the first half of 2025, with domestic drugs accounting for 40, showcasing an acceleration in the pace of innovation [1] - Shanghai has emerged as a key hub for biopharmaceuticals, with 9 innovative drugs approved for overseas markets in 2023, reflecting a shift from single breakthroughs to batch outputs [2][3] Industry Trends - The total number of global pharmaceutical transactions reached 682, with a total value of $191 billion in the first three quarters of 2025, indicating a strong upward trend [1] - Chinese pharmaceutical companies are transitioning from being participants in the global market to becoming significant contributors to global health [3][4] - The focus on "source innovation" is critical for Chinese companies to differentiate themselves and avoid homogenization in drug development [2][4] Challenges and Opportunities - Despite the growth, the Chinese pharmaceutical industry faces challenges such as weak foundational research and a predominance of "follow-up" innovation, leading to issues with target homogenization [2][6] - There is a pressing need for differentiation in innovation to create value, as highlighted by industry leaders [2][5] - The industry must address the affordability of innovations for the Chinese population, necessitating a shift in cost strategies compared to Western markets [5][6] Strategic Directions - Companies are encouraged to adopt a rational approach to innovation, focusing on unmet clinical needs and leveraging emerging technologies to address these demands [7][8] - The ability to sell drugs globally is becoming a key competitive advantage, with companies needing to build strong commercial capabilities alongside their R&D efforts [9][10] - Collaborative approaches and localized strategies are essential for navigating international markets effectively [10][11] Future Outlook - The potential for "source innovation" to drive the next wave of growth in the Chinese pharmaceutical industry is recognized, contingent on overcoming existing barriers [11]

Core Insights - China's pharmaceutical innovation is experiencing a significant increase in transaction volume, with overseas transactions exceeding $100 billion, indicating a robust growth in the sector [1][5] - The National Medical Products Administration (NMPA) has approved 43 new drugs in the first half of 2025, with a notable acceleration in the pace of innovation drug approvals [1][4] - Despite the growth in quantity, the quality of innovation remains a concern, with a predominance of "follow-up" innovation and issues of target homogeneity [2][6] Industry Trends - The global pharmaceutical transaction volume reached $191 billion in the first three quarters of 2025, with China contributing $937 billion, showcasing its competitive position in the global market [1][5] - Shanghai has emerged as a key hub for biopharmaceuticals, with 9 innovative drugs approved for overseas markets in 2023, leading the nation in this regard [4][5] - The shift from "single product authorization" to a focus on systemic capabilities and deep collaboration reflects a changing strategy among Chinese pharmaceutical companies [13] Challenges and Opportunities - The industry faces challenges such as weak foundational research, a trust crisis in collaborations, and funding difficulties, which hinder the development of truly innovative products [8][9] - There is a pressing need for differentiation in innovation, with a focus on "source innovation" to avoid the pitfalls of homogeneous competition [2][6][12] - Companies are encouraged to adopt a cost-effective approach to innovation, particularly in the context of China's large population and healthcare affordability [7][10] Strategic Directions - Companies must recognize unmet clinical needs and maintain a rational approach to innovation, avoiding overcrowding in competitive areas [9][10] - The ability to sell innovative drugs globally is becoming a critical measure of a company's success, surpassing mere research capabilities [12][14] - Building strong global commercialization capabilities through partnerships and localized teams is essential for navigating international markets [13][14]

Core Viewpoint - Shenzhen is actively exploring new production relationships and institutional frameworks to adapt to the development of new technologies and organizational systems, aiming to become a hub for innovative productivity [1][2]. Group 1: Innovation in Robotics and AI - The successful participation of humanoid robots in various public roles, including the recent torch relay, highlights Shenzhen's advancements in AI and robotics [2]. - The city is integrating innovation chains, industry chains, capital chains, and talent chains to establish itself as a source and incubator of new productivity [2]. Group 2: Government as an Innovation Partner - The establishment of specialized industry offices for pharmaceuticals, new energy vehicles, and artificial intelligence reflects a shift in government roles from mere management to active partnership in innovation [4]. - The newly formed Longgang District AI and Robotics Bureau aims to streamline planning, ecosystem development, and talent recruitment, showcasing a market-oriented approach to governance [5]. Group 3: Restructuring Source Innovation - Shenzhen's innovation ecosystem is being bolstered by the establishment of dedicated institutions like the Shenzhen Natural Science Fund Committee and the New Productivity Technology Promotion Center, focusing on both basic research and technology commercialization [7][8]. - The introduction of technical managers aims to bridge the gap between technology and market needs, enhancing the commercialization of research outcomes [8][9]. Group 4: Encouraging Capital Investment - The concept of "bold capital" has been introduced to encourage long-term investment in innovative enterprises, with initiatives like "Shenzhen Venture Capital Day" attracting significant participation from global investment institutions [11][12]. - The Shenzhen government has established various funds to support key industries, including a 5 billion yuan semiconductor investment fund, to strengthen the local innovation ecosystem [12]. Group 5: Embracing Failure in Innovation - Shenzhen's legal framework now supports entrepreneurs facing failure, allowing for personal bankruptcy and restructuring, which reduces the risks associated with innovation [12]. - The establishment of a comprehensive service platform for both corporate and personal bankruptcy reflects a commitment to fostering a culture that values innovation while being tolerant of failure [12].

Core Insights - The Photon Industry Summit at the 2025 Hard Technology Innovation Conference in Xi'an announced plans to tackle over 30 critical core technologies in the next two years, aiming to boost the output value of Shaanxi's photon industry to over 50 billion yuan [1] - The global photon market reached a scale of 920 billion USD in 2023 and is expected to exceed 1.2 trillion USD by 2027, driven by the explosion of AI technology [1] - The Shaanxi Photon Technology Laboratory, which has entered its cultivation phase with over 1 billion yuan in funding, aims to serve as a government think tank, innovation hub, and industry chain promoter [1] Development Plans - The laboratory's strategy is based on a dual approach of "source innovation + industry integration," with a spatial layout of "one laboratory and two bases" [2] - The core of "source innovation" is the advanced attosecond laser facility, which will integrate research resources from universities and institutes, focusing on fundamental research and technological breakthroughs [2] - The laboratory aims to establish a mechanism for "laying eggs along the way" to promote the industrial application of multiple achievements by 2030, aspiring to become a nationally influential photon technology laboratory [2] Industry Landscape - Since the launch of the "Chasing Light Plan" in 2021, Shaanxi has developed three core industrial clusters in photon materials and chips, advanced lasers and photon manufacturing, and photon sensing, with a total output value exceeding 35 billion yuan [2]

Core Viewpoint - Shenzhen is actively exploring innovative mechanisms and institutional reforms to adapt to new technologies and production relationships, positioning itself as a hub for new productive forces and innovation [1][2][3]. Group 1: Innovation and Government Role - The government of Shenzhen is evolving from a traditional management role to becoming an "innovation partner" and risk-sharer, particularly in emerging industries like AI and robotics [3][4]. - The establishment of specialized industry offices for pharmaceuticals, new energy vehicles, and artificial intelligence reflects a shift towards a more dynamic and responsive governance model [2][3]. Group 2: New Institutional Frameworks - The launch of the first government-affiliated institution for AI and robotics in Longgang District aims to enhance industry planning, ecosystem development, and service for enterprises [3][4]. - The new institution employs a "market-oriented personnel mechanism" and is actively recruiting global talent to drive innovation and technology planning [4]. Group 3: Research and Development Initiatives - Shenzhen is focusing on foundational research and technology transfer, with the Shenzhen Natural Science Foundation Committee supporting ten key areas, including advanced manufacturing and quantum computing [5][6]. - The establishment of the New Productive Forces Technology Promotion Center aims to create a comprehensive service matrix for technology transfer, integrating resources across academia and industry [6][7]. Group 4: Capital and Investment Strategies - Shenzhen is promoting "bold capital" to encourage long-term investment in innovation, with initiatives like "Shenzhen Venture Capital Day" attracting over 5,500 investment institutions [8][9]. - The city has set up various industry guidance funds, including a 5 billion yuan semiconductor investment fund, to support critical areas of the industry [9]. Group 5: Innovation Ecosystem and Cultural Shift - Shenzhen is redefining its innovation ecosystem by allowing for failure and providing legal frameworks for personal bankruptcy, which encourages entrepreneurship [9][10]. - The establishment of a comprehensive service platform for corporate and personal restructuring reflects a commitment to reducing the costs of innovation and fostering a culture that values both success and failure [9][10].